首頁 > 市場調查報告書 > 製藥

感染疾病

大環內酯類抗生素市場規模、佔有率及成長分析（依藥物、給藥途徑、適應症、最終用戶及地區分類）－產業預測，2026-2033年

市場調查報告書

商品編碼

1902325

大環內酯類抗生素市場規模、佔有率及成長分析（依藥物、給藥途徑、適應症、最終用戶及地區分類）－產業預測，2026-2033年

Macrolide Antibiotics Market Size, Share, and Growth Analysis, By Drugs (Azithromycin, Clarithromycin), By Administration (Oral, Parenteral), By Indication, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 218 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球大環內酯類抗生素市場規模將達到 59.3 億美元，到 2025 年將成長至 60.7 億美元，到 2033 年將成長至 72.8 億美元，預測期（2026-2033 年）的複合年成長率為 2.3%。

全球大環內酯類抗生素市場受感染疾病（尤其是呼吸道疾病和性行為感染感染疾病）日益普遍的推動。大環內酯類抗生素的特點是具有大環內酯結構，能夠抑制細菌蛋白質合成。它們通常表現出抑菌活性，但在高劑量下可表現出殺菌活性。它們廣泛用於治療肺炎、支氣管炎、沙眼衣原體感染和淋病等疾病。社區型肺炎發生率的上升，特別是由於人口結構變化，正在推動對這類抗生素的需求。此外，非專利大環內酯類抗生素的日益普及也促進了市場擴張，因為相關人員致力於開發現有品牌產品的成本效益更高的替代品。這一趨勢支持了大環內酯類抗生素市場佔有率擴張的戰略潛力。

全球大環內酯類抗生素市場促進因素

全球大環內酯類抗生素市場預計將迎來顯著成長，尤其是在中國、印度和巴西等新興經濟體。這些地區人口眾多，醫療保健成本不斷攀升，導致對高效抗生素的需求日益成長。此外，這些市場細菌感染疾病的日益普遍也為生產商提供了拓展業務、滿足市場對高效治療方案日益成長的需求的廣泛機會。隨著醫療基礎設施的不斷完善，大環內酯類抗生素市場有望受益於人們對健康問題的日益關注以及有效對抗感染疾病的迫切需求。

限制全球大環內酯類抗生素市場的因素

由於抗生素抗藥性微生物的日益增多，全球大環內酯類抗生素市場面臨嚴峻挑戰。這種抗藥性，尤其是對大環內酯類抗生素的抗藥性，主要是由於這些藥物的過度使用和不合理使用所造成的。隨著抗生素抗藥性的不斷增強，大環內酯類抗生素作為細菌感染疾病有效治療方法的長期療效可能會下降。為了應對這一令人擔憂的趨勢，必須開發創新藥物和替代治療策略，以有效對抗抗生素抗藥性細菌，並確保其在治療感染疾病的持續有效性。

全球大環內酯類抗生素市場趨勢

由於迫切需要應對日益嚴重的細菌抗藥性並提高治療效果，全球大環內酯類抗生素市場目前正經歷顯著成長。這一趨勢的特點是研發投入不斷增加，致力於開發新型大環內酯衍生物和具有更佳藥物動力學和更廣治療範圍的創新製劑。製藥公司正優先開發先進的大環內酯類抗生素，以應對不斷演變的微生物威脅並最佳化現有多種疾病的治療方法。這種積極進取的策略體現了製藥公司確保在對抗細菌感染疾病安全有效，並最終塑造大環內酯類抗生素市場未來的決心。

Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
AbbVie Inc.（USA）
Sanofi SA（France）
Novartis AG（Switzerland）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Mylan NV（USA）
Daiichi Sankyo Company, Limited（Japan）
Sun Pharmaceutical Industries Limited（India）
Cipla Limited（India）
Lupin Limited（India）
Zydus Lifesciences Limited（India）
Alkem Laboratories Ltd.（India）
Zhejiang Guobang Pharmaceutical Co., Ltd.（China）
Bristol Myers Squibb（USA）
Abbott Laboratories（USA）
Eli Lilly and Company（USA）
Amgen Inc.（USA）
Sandoz International GmbH（Germany）

結論與建議

簡介目錄

Product Code: SQMIG35I2327

Global Macrolide Antibiotics Market size was valued at USD 5.93 Billion in 2024 and is poised to grow from USD 6.07 Billion in 2025 to USD 7.28 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global market for macrolide antibiotics is being driven by an increase in infectious disease prevalence, particularly respiratory and sexually transmitted infections. Characterized by their macrocyclic lactone structure and ability to inhibit bacterial protein synthesis, macrolides, while typically bacteriostatic, can exhibit bactericidal effects at higher doses. They are widely utilized to treat conditions such as pneumonia, bronchitis, chlamydia, and gonorrhea. The rising incidence of community-acquired pneumonia, notably influenced by demographics, enhances the demand for these antibiotics. Additionally, the growing accessibility of generic macrolide options contributes to market expansion, as stakeholders focus on developing cost-effective alternatives to established brand-name products. This trend underscores the strategic potential for increased market share in the macrolide antibiotics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segments Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is poised for significant growth, particularly in emerging economies such as China, India, and Brazil. These regions, characterized by large populations and escalating healthcare expenses, demonstrate a heightened demand for effective antibiotics. Moreover, the increasing prevalence of bacterial infections in these markets creates ample opportunities for manufacturers to expand their presence and tap into the growing need for efficient treatment solutions. As healthcare infrastructure continues to develop, the macrolide antibiotics sector stands to benefit from the rising awareness of health issues and the urgency to address infectious diseases effectively.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant challenges due to the increasing prevalence of microorganisms that have developed resistance to antibiotics. This resistance, especially to macrolides, stems largely from the overuse and inappropriate use of these medications. As antibiotic resistance rises, the long-term viability of macrolide antibiotics as effective treatments for bacterial infections may diminish. Addressing this concerning trend necessitates the development of innovative drugs and alternative therapeutic strategies to effectively combat antibiotic-resistant bacteria and ensure continued efficacy in treating infections.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is currently experiencing significant growth, driven by the urgent need to combat rising bacterial resistance and enhance treatment efficacy. This trend is characterized by increased research and development efforts aimed at creating novel macrolide derivatives and innovative formulations that improve pharmacokinetics and broaden their therapeutic range. Pharmaceutical companies are prioritizing the development of advanced macrolide antibiotics to address evolving microbial threats and optimize existing treatments for diverse illnesses. This proactive approach reflects a commitment to ensuring safety and effectiveness in combating bacterial infections, ultimately shaping the future landscape of the macrolide antibiotic market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2026-2033)

Market Overview
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2026-2033)

Market Overview
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Dermatology clinics
Pharmaceutical companies
Others

Global Macrolide Antibiotics Market Size & CAGR (2026-2033)

North America (Drugs, Administration, Indication, End User)
- US
- Canada
Europe (Drugs, Administration, Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drugs, Administration, Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drugs, Administration, Indication, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drugs, Administration, Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkem Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments